Across 559 plasma samples spanning 24 cancer types and clinically relevant tumor fractions, APEX outperforms existing approaches for individual-gene inference, resolves pancreatic cancer transcriptional subtypes, tracks therapeutic targets in small-cell lung cancer, and identifies NECTIN4 expression as a biomarker of r...
G. Gulati, D. Vasseur, R. Nawfal et al.· Research Square· 0 citations
The combination of azenosertib and gemcitabine was associated with substantial myelosuppression in patients with metastatic PDAC previously treated with FOLFIRINOX, limiting further clinical evaluation of this dosing strategy.
B. Huffman, Haeseong Park, Nadine A. Jackson et al.· Cancer Research· 0 citations
It is suggested that productive immunotherapy responses in PDAC require not only tumor-reactive T cells, but also a stromal-vascular niche capable of supporting their recruitment, recirculation and persistence.
Sarah Kang, M. Parikh, Leontios Pappas et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed at an advanced stage with limited treatment options. Patient-derived organoids (PDOs) can model tumors, identify determinants of therapeutic response, and support precision medicine. In the multi-institutional PASS-01 trial of metastatic PDAC, biopsies f...
A. Habowski, Fatim M. Kouassi, James A. Rouse et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
